{
    "organizations": [],
    "uuid": "86b321ef284d303a3fb08145315d21640a78f92e",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pulmatrix-announces-first-subject/brief-pulmatrix-announces-first-subject-dosed-in-phase-1-clinical-trial-of-pulmazole-idUSASB0C583",
    "ord_in_thread": 0,
    "title": "BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 13 PM / in 14 minutes BRIEF-Pulmatrix Announces First Subject Dosed In Phase 1 Clinical Trial Of Pulmazole Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Pulmatrix Inc: \n* PULMATRIX ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSEâ„¢ FORMULATION OF ITRACONAZOLE \n* PHASE 1 DATA FOR CLINICAL TRIAL OF PULMAZOLE IS EXPECTED IN MID-2018 Source text for Eikon: Further company coverage:",
    "published": "2018-02-12T17:13:00.000+02:00",
    "crawled": "2018-02-12T17:36:12.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "announces",
        "first",
        "subject",
        "dosed",
        "phase",
        "clinical",
        "trial",
        "pulmazole",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "pulmatrix",
        "inc",
        "pulmatrix",
        "announces",
        "first",
        "subject",
        "dosed",
        "phase",
        "clinical",
        "trial",
        "pulmazole",
        "inhaled",
        "formulation",
        "itraconazole",
        "phase",
        "data",
        "clinical",
        "trial",
        "pulmazole",
        "expected",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}